Latest ASX Announcements

Quarterly Review – Q2 FY2018

Quarter highlights

  • DMX-200 Phase 2a in Chronic Kidney Disease sub-group analysis was released in November showing compelling efficacy signals in the Diabetic Nephropathy sub-group.
  • Trial data was presented at the ASN Kidney Week in New Orleans, BIO- Europe in Berlin, the World Congress in Clinical Trials in Diabetes in Berlin and, post quarter, to meetings […]
By | 2018-01-30T08:29:57+00:00 January 30th, 2018|Latest ASX Announcements|

Results of Entitlement Offer

Dimerix Limited or the “Company” (ASX: DXB), a clinical stage biotechnology company today announces results from its 1 for 2 pro-rata non-renounceable Entitlement Offer of fully paid ordinary shares in Dimerix announced on 6 December 2017, opened on 13 December 2017 and closed on 19 January 2018.

View the full release here. 

By | 2018-01-24T06:50:33+00:00 January 24th, 2018|Latest ASX Announcements|

Recorded interview with CEO and rights issue reminder

The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 at 7:00pm AEDT (Sydney time).

Funds raised are important for the commercialisation of DMX-200 across the Chronic Kidney Disease areas of FSGS and Diabetic Nephropathy

An Entitlement and Acceptance form has been mailed to shareholders, and […]

By | 2018-01-16T07:17:05+00:00 January 16th, 2018|Latest ASX Announcements|

DMX-200 Dosage Optimisation Study Successfully Completed in Preparation for Phase 2b trial

Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program targeting Chronic Kidney Disease (CKD).

The study found a newly formulated extended release tablet of DMX-200 taken twice daily (against three times daily for the previous formulation) increases the duration of release of DMX-200 in […]

By | 2018-01-08T08:19:43+00:00 January 8th, 2018|Latest ASX Announcements|

Dimerix and Proteomics partner to improve treatment of Chronic Kidney Disease

MELBOURNE, Australia, 14 December 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company is pleased to announce that it has partnered with a leader in predictive diagnostics, Proteomics International (ASX:PIQ), to improve the treatment of Chronic Kidney Disease (CKD).

Proteomics International (PI) has developed PromarkerD, a predictive and diagnostic test for diabetic kidney disease that […]

By | 2017-12-14T07:17:04+00:00 December 14th, 2017|Latest ASX Announcements|

Dimerix rights issue audio interview with CEO Kathy Harrison

Dimerix announced last week that it would offer shareholders the opportunity to participate in an Entitlement Offer to raise up to $5.5m. Funds raised would drive the company’s lead drug development program, DMX-200 to its nearest commercial inflection point. In this interview, Boardroom Media’s Co-Founder, Bill Gair interviews Dimerix’s CEO, Kathy Harrison about the company’s […]

By | 2017-12-14T17:55:16+00:00 December 11th, 2017|Latest ASX Announcements|